Drugs / NTRX-07
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06194552 | Sep 2022 → May 2023 | Alzheimer disease | NeuroTherapia, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07058688 | Mar → Dec 2025 overdue | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | NeuroTherapia, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | NeuroTherapia, Inc. | Results NeuroTherapia to Present Phase 2a Alzheimer’s Disease Clinical Data at the AAIC 2026 Conference in London, UK neurotherapia.com ↗
Across several brain regions, descriptive analyses favored the NTRX-07 group on measures of neuroinflammation, with some areas showing statistically significant changes and other demonstrating directionally consistent trends toward reduced neurodegeneration. |
| 2026-04-07 | NeuroTherapia, Inc. | Results NeuroTherapia announces completion of its Phase 2a Trial of a novel treatment for Alzheimer's Disease neurotherapia.com ↗
Preliminary analysis of exploratory endpoints, including MRI, qEEG, and CSF biomarkers, indicates some encouraging results. |
| 2023-10-24 | NeuroTherapia, Inc. | Results NeuroTherapia Presents Clinical Data from Phase 1b Clinical Trial of NTRX-07 for the Treatment of Alzheimer’s Disease neurotherapia.com ↗
Data from the study demonstrated a favorable safety profile at all dose ranges, a pharmacokinetic (PK) profile consistent with preclinical studies and in line with levels expected to drive clinical activity, and a trend toward cognitive improvement in the AD patients that were treated with NTRX-07. |
| 2020-12-01 | NeuroTherapia, Inc. | Results NeuroTherapia Announces Completion of Phase 1a Clinical Trial neurotherapia.com ↗
Levels of NTRX-07 measured in the blood were 2-4 fold higher than those predicted from preclinical studies. |
| 2019-10-13 | NeuroTherapia, Inc. | Regulatory NeuroTherapia to Start Clinical Trials of NTRX-07 For Alzheimer’s Disease neurotherapia.com ↗
The U.S. Food and Drug Administration (FDA) accepted the IND filing which allows NeuroTherapia to begin its first-in-human studies of NTRX-07 in an ascending dose study in normal healthy volunteers, which is scheduled to begin in mid-summer. |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTRX-07 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06194552 ↗ |
| Action | Activate | “Investigational orally administered CB2 agonist” NCT06194552 ↗ |
| Route | Oral | “NTRX-07 administered orally once per day for 7 days” NCT06194552 ↗ |